1. Home
  2. RARE
  3. RARE News

Latest Ultragenyx Pharmaceutical Inc. (RARE) News on April 2, 2025

Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy
RARE

Insider Monkey

3 days ago

Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

13 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx price target lowered to $115 from $140 at Piper Sandler
RARE

TipRanks

15 days ago

Ultragenyx price target lowered to $115 from $140 at Piper Sandler

Ultragenyx to Participate at Investor Conferences in March
RARE

GlobeNewswire

a month ago

Ultragenyx to Participate at Investor Conferences in March

Exploring Three High Growth Tech Stocks in the United States
RARE

Simply Wall St.

a month ago

Exploring Three High Growth Tech Stocks in the United States

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

a month ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

MT Newswires

a month ago

Ultragenyx Pharmaceutical Eyes Aug. 18 FDA Approval for Sanfilippo Syndrome Gene Therapy Treatment

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
RARE

GlobeNewswire

a month ago

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
RARE

Simply Wall St.

a month ago

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

RARE

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call

Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
RARE

Zacks

2 months ago

Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y

Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
RARE

GuruFocus.com

2 months ago

Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

RARE

MT Newswires

2 months ago

Ultragenyx Pharmaceutical Q4 Net Loss Narrows, Revenue Rises

RARE

Associated Press Finance

2 months ago

Ultragenyx: Q4 Earnings Snapshot

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

2 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

2 months ago

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
RARE

Zacks

2 months ago

RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study

Ultragenyx announces new data on UX111 AV gene therapy
RARE

TipRanks

2 months ago

Ultragenyx announces new data on UX111 AV gene therapy

RARE

MT Newswires

2 months ago

Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS
RARE

GlobeNewswire

2 months ago

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

RARE

MT Newswires

2 months ago

Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $47 From $48, Keeps Neutral Rating

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

2 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential
RARE

Insider Monkey

2 months ago

Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
RARE

Benzinga

3 months ago

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
RARE

GlobeNewswire

3 months ago

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
RARE

Zacks

3 months ago

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
RARE

GlobeNewswire

3 months ago

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder
RARE

Pharmaceutical Technology

3 months ago

Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
RARE

GlobeNewswire

3 months ago

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

RARE

MT Newswires

3 months ago

Ultragenyx Pharmaceutical Insider Sold Shares Worth $495,231, According to a Recent SEC Filing

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

3 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
RARE

Zacks

3 months ago

RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)
RARE

GlobeNewswire

3 months ago

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

RARE

MT Newswires

3 months ago

Ultragenyx Reports Patient Dosing in Angelman Syndrome Trial

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
RARE

GlobeNewswire

3 months ago

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

RARE

MT Newswires

3 months ago

Ultragenyx Seeks FDA Accelerated Approval for Gene Therapy to Treat Sanfilippo Syndrome

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
RARE

GlobeNewswire

3 months ago

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx to Participate in Investor Conferences in December
RARE

GlobeNewswire

4 months ago

Ultragenyx to Participate in Investor Conferences in December

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

4 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
RARE

GlobeNewswire

5 months ago

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations
RARE

Simply Wall St.

5 months ago

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations

Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
RARE

Zacks

5 months ago

Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates

Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ...
RARE

GuruFocus.com

5 months ago

Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ...

RARE

MT Newswires

5 months ago

Ultragenyx Pharmaceutical Q3 Net Loss Narrows, Revenue Rises; Shares Fall After Hours

RARE

Associated Press Finance

5 months ago

Ultragenyx: Q3 Earnings Snapshot

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

5 months ago

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?
RARE

Insider Monkey

5 months ago

What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

5 months ago

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year
RARE

Simply Wall St.

5 months ago

Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

5 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 10/15/2024

RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
RARE

Zacks

6 months ago

RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag

RARE

MT Newswires

6 months ago

Ultragenyx's Setrusumab Receives FDA Breakthrough Therapy Designation

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
RARE

GlobeNewswire

6 months ago

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

RARE's Wilson Disease Candidate Betters Standard Therapy in Study
RARE

Zacks

6 months ago

RARE's Wilson Disease Candidate Betters Standard Therapy in Study

RARE

MT Newswires

6 months ago

Ultragenyx Pharmaceutical Wilson Disease Therapy Study Shows Meaningful Data

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
RARE

GlobeNewswire

6 months ago

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
RARE

GlobeNewswire

6 months ago

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

6 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

MT Newswires

7 months ago

Ultragenyx Pharmaceutical Insider Sold Shares Worth $1,117,000, According to a Recent SEC Filing

Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now
RARE

Insider Monkey

7 months ago

Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Ultragenyx to Participate in Investor Conferences in September
RARE

GlobeNewswire

7 months ago

Ultragenyx to Participate in Investor Conferences in September

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

7 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

MT Newswires

8 months ago

Ultragenyx Pharmaceutical Insider Sold Shares Worth $1,003,400, According to a Recent SEC Filing

RARE

MT Newswires

8 months ago

Wedbush Adjusts Ultragenyx Pharmaceutical's PT to $46 From $43, Keeps Neutral Rating

Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
RARE

Zacks

8 months ago

Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up

RARE

Associated Press Finance

8 months ago

Ultragenyx: Q2 Earnings Snapshot

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

8 months ago

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

8 months ago

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
RARE

GlobeNewswire

8 months ago

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
RARE

Investor's Business Daily

8 months ago

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

8 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
RARE

Zacks

8 months ago

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans

RARE

MT Newswires

8 months ago

Ultragenyx Reports 'Successful' End-of-Phase 2 FDA Meeting For Angelman Syndrome Program

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
RARE

GlobeNewswire

8 months ago

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

9 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

MT Newswires

10 months ago

Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating

RARE

MT Newswires

10 months ago

Ultragenyx Pharmaceutical Prices $350 Million Offering

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
RARE

GlobeNewswire

10 months ago

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
RARE

Zacks

10 months ago

Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug

Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
RARE

Simply Wall St.

10 months ago

Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Insider Sale: EVP and Chief Legal Officer Karah Parschauer Sells Shares of Ultragenyx ...
RARE

GuruFocus.com

10 months ago

Insider Sale: EVP and Chief Legal Officer Karah Parschauer Sells Shares of Ultragenyx ...

RARE

MT Newswires

10 months ago

Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025

RARE

MT Newswires

10 months ago

Ultragenyx Pharmaceutical Launches Equity Offering

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
RARE

GlobeNewswire

10 months ago

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
RARE

GlobeNewswire

10 months ago

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

RARE

MT Newswires

10 months ago

Update: Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate

Ultragenyx (RARE) Posts New Data From Bone Disease Study
RARE

Zacks

10 months ago

Ultragenyx (RARE) Posts New Data From Bone Disease Study

RARE

MT Newswires

10 months ago

Sector Update: Health Care

Ultragenyx, Mereo drug reduces fractures in bone disorder study
RARE

BioPharma Dive

10 months ago

Ultragenyx, Mereo drug reduces fractures in bone disorder study

RARE

MT Newswires

10 months ago

Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
RARE

GlobeNewswire

10 months ago

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

RARE

MT Newswires

10 months ago

Goldman Sachs Upgrades Ultragenyx Pharmaceutical to Buy From Neutral, Raises Price Target to $67 From $56

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
RARE

GlobeNewswire

10 months ago

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

RARE

MT Newswires

10 months ago

Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating

Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
RARE

Zacks

10 months ago

Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study

RARE

MT Newswires

10 months ago

Baird Raises Price Target on Ultragenyx Pharmaceutical to $72 From $68, Maintains Outperform Rating

RARE

MT Newswires

10 months ago

Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $48 From $47, Keeps Neutral Rating

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
RARE

GlobeNewswire

10 months ago

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
RARE

Benzinga

10 months ago

Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells

Share on Social Networks: